Preeclampsia Severe Clinical Trial
Official title:
Eculizumab in HELLP Syndrome
This research study is being performed to see if women diagnosed with early preterm Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) syndrome (estimated gestational ages of 23-30 weeks) benefit from a medication called eculizumab (ECU). This drug blocks a part of the immune system called complement. By blocking this part of the immune system, eculizumab may stop or reverse the progression of the HELLP syndrome disease. The investigators will also look to see if this drug is effective and benefits both the mother and fetus.
Preeclampsia is a devastating multisystem disorder of pregnancy that manifests as hypertension with or without proteinuria and/or end organ damage caused by endothelial dysfunction and occurs in 3-5% of all pregnancies. Notably, preeclampsia accounts for 30% of all preterm deliveries, which results in neonatal intensive care unit admissions, increased health care cost, severe neonatal morbidity, and neonatal mortality. HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome is the most severe variant of this disorder, and affects approximately 0.1-0.2% of all pregnancies. Despite its prevalence, the cellular biology of HELLP syndrome is unclear resulting in supportive treatment regimens like fetal monitoring, steroids for fetal lung maturity, magnesium for seizure prophylaxis, management of hypertension and ultimately delivery that results in iatrogenic preterm birth. Complement is an enzymatic cascade of approximately 50 proteins which are activated by the classic pathway of complement, the lectin pathway of complement, and the alternative pathway of complement (APC). While the classic pathway depends on antigen-antibody complexes (i.e., lupus) for activation, the APC is antibody independent and has various triggers including infection, trauma, and pregnancy. The investigators' research lab created a novel functional assay, the modified Ham (mHam) assay, to diagnose highly morbid diseases of the APC such atypical hemolytic uremic syndrome (aHUS). Because of the phenotypic similarities of aHUS and HELLP syndrome the investigators' lab undertook a study to test women diagnosed with complete (classic) HELLP and partial (atypical) HELLP syndrome established by Tennessee and American College of Obstetrics and Gynecology (ACOG) criteria to observe if there was dysregulation and overactivation of the APC. The investigators found that most women with HELLP syndrome have APC upregulation; furthermore, it could be inhibited in vitro with anti-C5 monoclonal antibody. In addition, the investigators recently showed approximately 50% of women with HELLP syndrome have germline mutations associated with regulatory proteins of the APC 12. These are the same mutations associated with aHUS; further, 4 of the 5 women with germline mutations are positive by the mHam assay correlating genotype to phenotype. With the investigators' current data that HELLP syndrome is similar to aHUS, the investigators propose an open label clinical trial of ECU administration to women with HELLP syndrome at 23-30 weeks gestation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04243278 -
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
|
Early Phase 1 | |
Not yet recruiting |
NCT03318211 -
Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT05594056 -
Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia.
|
N/A | |
Recruiting |
NCT03761888 -
Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
|
||
Not yet recruiting |
NCT06373367 -
Preeclampsia Educational Program Study (PrEPS)
|
N/A | |
Not yet recruiting |
NCT04855513 -
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
|
N/A | |
Not yet recruiting |
NCT05232994 -
Metformin and Esomeprazole For Preterm Pre-eclampsia
|
Phase 1 | |
Completed |
NCT04392375 -
Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
|
Phase 4 | |
Recruiting |
NCT03978767 -
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial
|
Phase 2 | |
Completed |
NCT04236258 -
Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period
|
Phase 4 | |
Completed |
NCT04756661 -
Uterotonics for Severe Preeclampsia
|
N/A | |
Active, not recruiting |
NCT04660032 -
Nudge to Drive Transitions of Care
|
N/A | |
Enrolling by invitation |
NCT04794855 -
Risk Prediction Model of Preeclampsia
|
||
Recruiting |
NCT04311749 -
Expanded NIPT for Pregnancy Complications
|
||
Active, not recruiting |
NCT06359015 -
Metformin and Esomeprazole in Preterm Pre-eclampsia
|
Phase 4 | |
Recruiting |
NCT05610774 -
Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine
|
N/A | |
Completed |
NCT03815110 -
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
|
||
Completed |
NCT03210350 -
Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
|
||
Completed |
NCT03451266 -
Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia
|
Phase 1 | |
Active, not recruiting |
NCT06360601 -
Intravenous Labetalol Versus Hydralazine in Preeclampsia
|
Phase 1/Phase 2 |